Testing Elranatamab for newly diagnosed light chain amyloidosis
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether a new antibody drug called elranatamab can help treat newly diagnosed AL amyloidosis (a disease where abnormal proteins build up in organs). If you haven't had treatment yet and have confirmed AL amyloidosis, this trial may offer access to an experimental therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed AL amyloidosis with no prior treatment
- Tissue biopsy confirming AL amyloidosis (Congo red stain and light chain type identified)
- No myeloma-defining events (except very high light chain ratios alone)
- Age 18 or older with good enough overall health (ECOG score 0–2)
- Normal enough blood cell counts and liver/kidney function
- Cardiac stage I, II, or IIIa disease (not the most severe stage IIIB)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
This trial tests a combination of three drugs — daratumumab, pomalidomide, and dexamethasone — for people newly diagnosed with AL amyloidosis. The goal is to see if this treatment helps reduce the abnormal proteins and improve organ function.
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
Hear when a new Amyloid Light-chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.